Probabilistic risk assessment of gold nanoparticles after intravenous administration by integrating in vitro and in vivo toxicity with physiologically based pharmacokinetic modeling

References

• Andersen, M.E., M. B. Black, J. L. Campbell, S. N. Pendse, H. J. Clewell, III, L. H. Pottenger, J. S. Bus, et al. 2017. “Combining Transcriptomics and PBPK Modeling Indicates a Primary Role of Hypoxia and Altered Circadian Signaling in Dichloromethane Carcinogenicity in Mouse Lung and Liver.” Toxicology and Applied Pharmacology 332: 149–158.
   PubMed Web of Science ®Google Scholar
• Arvizo, R. R., S. Bhattacharyya, R. A. Kudgus, K. Giri, R. Bhattacharya, and P. Mukherjee. 2012. “Intrinsic Therapeutic Applications of Noble Metal Nanoparticles: Past, Present and Future.” Chemical Society Reviews 41 (7): 2943–2970.
   PubMed Web of Science ®Google Scholar
• Bachler, G., N. von Goetz, and K. Hungerbühler. 2013. “A Physiologically based Pharmacokinetic Model for Ionic Silver and Silver Nanoparticles.” International Journal of Nanomedicine 8:3365–3382.
   PubMed Web of Science ®Google Scholar
• Bachler G, von Goetz N, Hungerbuhler K. 2015. “Using Physiologically based Pharmacokinetic (PBPK) Modeling for Dietary Risk Assessment of Titanium Dioxide (TiO2) Nanoparticles.” Nanotoxicology 9 (3): 373–380.
   PubMed Web of Science ®Google Scholar
• Balasubramanian, S. K., J. Jittiwat, J. Manikandan, C. N. Ong, L. E. Yu, and W. Y. Ong. 2010. “Biodistribution of Gold Nanoparticles and Gene Expression Changes in the Liver and Spleen after Intravenous Administration in Rats. Biomaterials 31 (8): 2034–2042.
   PubMed Web of Science ®Google Scholar
• Bhatt, I., and B. N. Tripathi. 2011. “Interaction of Engineered Nanoparticles with Various Components of the Environment and Possible Strategies for their Risk Assessment.” Chemosphere 82 (3):308–317.
   PubMed Web of Science ®Google Scholar
• Bois, F. Y., M. Jamei, and H. J. Clewell. 2010. “PBPK Modelling of Inter-individual Variability in the Pharmacokinetics of Environmental Chemicals.” Toxicology 278 (3): 256–267.
   PubMed Web of Science ®Google Scholar
• Casals, E., T. Pfaller, A. Duschl, G. J. Oostingh, and V. Puntes. 2010. “Time Evolution of the Nanoparticle Protein Corona.” ACS Nano 4 (7): 3623–3632.
   PubMed Web of Science ®Google Scholar
• Chandran, P., J. E. Riviere, and N. A. Monteiro-Riviere. 2017. “Surface Chemistry of Gold Nanoparticles Determines the Biocorona Composition Impacting Cellular Uptake, Toxicity and Gene Expression Profiles in Human Endothelial Cells.” Nanotoxicology 11 (4): 507–519.
   PubMed Web of Science ®Google Scholar
• Chen, Y. S., Y. C. Hung, I. Liau, and G. S. Huang. 2009. “Assessment of the In Vivo Toxicity of Gold Nanoparticles.” Nanoscale Research Letters 4 (8): 858–864.
   PubMed Web of Science ®Google Scholar
• Cheng, Y.-H., Y.-J. Lin, S.-H. You, Y.-F. Yang, C. M. How, Y.-T. Tseng, W.-Y. Chen, and C.-M. Liao. 2016. “Assessing Exposure Risks for Freshwater Tilapia Species Posed by Mercury and Methylmercury.” Ecotoxicology 25 (6): 1181–1193.
   PubMed Web of Science ®Google Scholar
• Cho, W.-S., M. Cho, J. Jeong, M. Choi, H.-Y. Cho, B. S. Han, S. H. Kim, et al. 2009. “Acute Toxicity and Pharmacokinetics of 13 nm-Sized PEG-Coated Gold Nanoparticles.” Toxicology and Applied Pharmacology 236 (1): 16–24.
   PubMed Web of Science ®Google Scholar
• Choi, K., J. E. Riviere, and N. A. Monteiro-Riviere. 2017. “Protein Corona Modulation of Hepatocyte Uptake and Molecular Mechanisms of Gold Nanoparticle Toxicity.” Nanotoxicology 11 (1): 64–75.
   PubMed Web of Science ®Google Scholar
• Cohen, J. M., J. G. Teeguarden, and P. Demokritou. 2014. “An Integrated Approach for the In Vitro Dosimetry of Engineered Nanomaterials.” Particle and Fibre Toxicology 11:20.
   PubMed Web of Science ®Google Scholar
• Cordes, H., C. Thiel, V. Baier, L. M. Blank, and L. Kuepfer. 2018. “Integration of Genome-Scale Metabolic Networks into Whole-Body PBPK Models Shows Phenotype-Specific Cases of Drug-Induced Metabolic Perturbation.” NPJ Systems Biology and Applications 4:10.
   PubMed Web of Science ®Google Scholar
• DeLoid, G. M., J. M. Cohen, G. Pyrgiotakis, and P. Demokritou. 2017. “Preparation, Characterization, and In Vitro Dosimetry of Dispersed, Engineered Nanomaterials.” Nature Protocols 12 (2): 355–371.
   PubMed Web of Science ®Google Scholar
• EPA. 2012. Benchmark Dose Technical Guidance. Washington, DC: U.S. Environmental Protection Agency (EPA). https://www.epa.gov/sites/production/files/2015-01/documents/benchmark_dose_guidance.pdf.
   Google Scholar
• EPA. 2014. Probabilistic Risk Assessment to Inform Decision Making: Frequently Asked Questions. Washington, DC: U.S. EPA. https://www.epa.gov/sites/production/files/2014-11/documents/raf-pra-faq-final.pdf.
   Google Scholar
• Hinderliter, P. M., K. R. Minard, G. Orr, W. B. Chrisler, B. D. Thrall, J. G. Pounds, and J. G. Teeguarden. 2010. “ISDD: A Computational Model of Particle Sedimentation, Diffusion and Target Cell Dosimetry for In Vitro Toxicity Studies.” Particle and Fibre Toxicology 7 (1): 36.
   PubMedGoogle Scholar
• Hirn S., M. Semmler-Behnke, C. Schleh, A. Wenk, J. Lipka, M. Schäffler, S. Takenaka, et al. 2011. “Particle Size-Dependent and Surface Charge-Dependent Biodistribution of Gold Nanoparticles after Intravenous Administration.” European Journal of Pharmaceutics and Biopharmaceutics 77 (3): 407–416.
   PubMed Web of Science ®Google Scholar
• Jain, S., D. G. Hirst, and J. M. O'Sullivan. 2012. “Gold Nanoparticles as Novel Agents for Cancer Therapy.” British Journal of Radiology 85 (1010): 101–113.
   PubMed Web of Science ®Google Scholar
• James, W. D., L. R. Hirsch, J. L. West, P. D. O’Neal, and J. D. Payne. 2007. “Application of INAA to the Build-up and Clearance of Gold Nanoshells in Clinical Studies in Mice.” Journal of Radioanalytical and Nuclear Chemistry 271 (2): 455–459.
   Web of Science ®Google Scholar
• Jo, M. R., S. H. Bae, M. R. Go, H. J. Kim, Y. G. Hwang, and S. J. Choi. 2015. “Toxicity and Biokinetics of Colloidal Gold Nanoparticles.” Nanomaterials (Basel) 5 (2): 835–850.
   PubMedGoogle Scholar
• Johnston, H., G. Pojana, S. Zuin, N. R. Jacobsen, P. Møller, S. Loft, M. Semmler-Behnke, et al. 2013. Engineered Nanomaterial Risk. Lessons Learnt from Completed Nanotoxicology Studies: Potential Solutions to Current and Future Challenges.” Critical Reviews in Toxicology 43 (1): 1–20.
   PubMed Web of Science ®Google Scholar
• Khlebtsov, N., and L. Dykman. 2011. “Biodistribution and Toxicity of Engineered Gold Nanoparticles: A Review of In Vitro and In Vivo Studies.” Chemical Society Reviews 40 (3): 1647–1671.
   PubMed Web of Science ®Google Scholar
• Kreyling W. G., S. Hirn, W. Möller, C. Schleh, A. Wenk, G. Celik, J. Lipka, et al. 2014. “Air-Blood Barrier Translocation of Tracheally Instilled Gold Nanoparticles Inversely Depends on Particle Size.” ACS Nano 8 (1): 222–233.
   PubMed Web of Science ®Google Scholar
• Kreyling, W. G., U. Holzwarth, N. Haberl, J. Kozempel, S. Hirn, A. Wenk, et al. 2017a. “Quantitative Biokinetics of Titanium Dioxide Nanoparticles after Intravenous Injection in Rats: Part 1.” Nanotoxicology 11: 434–442.
   PubMed Web of Science ®Google Scholar
• Kreyling, W. G., U. Holzwarth, N. Haberl, J. Kozempel, A. Wenk, S. Hirn, et al. 2017c. “Quantitative Biokinetics of Titanium Dioxide Nanoparticles after Intratracheal Instillation in Rats: Part 3.” Nanotoxicology 11: 454–464.
   PubMed Web of Science ®Google Scholar
• Kreyling, W. G., U. Holzwarth, C. Schleh, J. Kozempel, A. Wenk, N. Haberl, et al. 2017b. “Quantitative Biokinetics of Titanium Dioxide Nanoparticles after Oral Application in Rats: Part 2.” Nanotoxicology 11: 443–453.
   PubMed Web of Science ®Google Scholar
• Kuempel, E. D., L. M. Sweeney, J. B. Morris, and A. M. Jarabek. 2015. “Advances in Inhalation Dosimetry Models and Methods for Occupational Risk Assessment and Exposure Limit Derivation.” Journal of Occupational and Environmental Hygiene 12(suppl 1): S18–S40.
   PubMed Web of Science ®Google Scholar
• Li, M., R. Gehring, J. E. Riviere, and Z. Lin. 2017a. “Development and Application of a Population Physiologically based Pharmacokinetic Model for Penicillin G in Swine and Cattle for Food Safety Assessment.” Food and Chemical Toxicology 107: 74–87.
   PubMed Web of Science ®Google Scholar
• Li, M., P. Zou, K. Tyner, and S. Lee. 2017b. “Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles.” AAPS Journal 19: 26–42.
   PubMed Web of Science ®Google Scholar
• Li, Y., and N. A. Monteiro-Riviere. 2016. “Mechanisms of Cell Uptake, Inflammatory Potential and Protein Corona Effects with Gold Nanoparticles.” Nanomedicine (London) 11 (24): 3185–3203.
   PubMed Web of Science ®Google Scholar
• Lin, Z., M. Jaberi-Douraki, C. He, S. Jin, R. S. H. Yang, J. W. Fisher, J. E. Riviere, et al. 2017. “Performance Assessment and Translation of Physiologically based Pharmacokinetic Models from acslX™ to Berkeley Madonna™, MATLAB®, and R Language: Oxytetracycline and Gold Nanoparticles as Case Examples.” Toxicological Sciences, 158 (1): 23–35.
   PubMed Web of Science ®Google Scholar
• Lin, Z., N. A. Monteiro-Riviere, R. Kannan, and J. E. Riviere. 2016a. “A Computational Framework for Interspecies Pharmacokinetics, Exposure and Toxicity Assessment of Gold Nanoparticles.” Nanomedicine (London) 11: 107–119.
   PubMed Web of Science ®Google Scholar
• Lin, Z., N. A. Monteiro-Riviere, and J. E. Riviere. 2015. “Pharmacokinetics of Metallic Nanoparticles.” Wiley Interdisciplinary Reviews: Nanomedicine Nanobiotechnology 7 (2): 189–217.
   PubMed Web of Science ®Google Scholar
• Lin, Z., N. A. Monteiro-Riviere, and J. E. Riviere. 2016b. “A Physiologically based Pharmacokinetic Model for Polyethylene Glycol-Coated Gold Nanoparticles of Different Sizes in Adult Mice.” Nanotoxicology 10: 162–172.
   PubMed Web of Science ®Google Scholar
• Mahapatra, I., T. Y. Sun, J. R. A. Clark, P. J. Dobson, K. Hungerbuehler, R. Owen, B. Nowack, et al. 2015. “Probabilistic Modelling of Prospective Environmental Concentrations of Gold Nanoparticles from Medical Applications as a Basis for Risk Assessment.” Journal of Nanobiotechnology 13: 93.
   PubMed Web of Science ®Google Scholar
• Maldonado, E. M., V. Leoncikas, C. P. Fisher, J. B. Moore, N. J. Plant, and A. M. Kierzek. 2017. “Integration of Genome Scale Metabolic Networks and Gene Regulation of Metabolic Enzymes with Physiologically Based Pharmacokinetics.” CPT: Pharmacometrics & Systems Pharmacology 6 (11): 732–746.
   PubMedGoogle Scholar
• Mannerström, M., J. Zou, T. Toimela, I. Pyykkö, and T. Heinonen. 2016. “The Applicability of Conventional Cytotoxicity Assays to Predict Safety/Toxicity of Mesoporous Silica Nanoparticles, Silver and Gold Nanoparticles and Multi-Walled Carbon Nanotubes.” Toxicology In Vitro 37: 113–120.
   PubMed Web of Science ®Google Scholar
• Monteiro-Riviere, N. A., A. O. Inman, and L. W. Zhang. 2009. “Limitations and Relative Utility of Screening Assays to Assess Engineered Nanoparticle Toxicity in a Human Cell Line.” Toxicology and Applied Pharmacology 234 (2): 222–235.
   PubMed Web of Science ®Google Scholar
• Nair, A. B., and S. A. Jacob. 2016. “A Simple Practice Guide for Dose Conversion Between Animals and Human.” Journal of Basic and Clinical Pharmacy 7 (2): 27–31.
   PubMedGoogle Scholar
• Noël, C., J. C. Simard, and D. Girard. 2016. “Gold Nanoparticles Induce Apoptosis, Endoplasmic Reticulum Stress Events and Cleavage of Cytoskeletal Proteins in Human Neutrophils.” Toxicology In Vitro 31: 12–22.
   PubMed Web of Science ®Google Scholar
• NRC (National Research Council) 2009. Science and Decisions: Advancing Risk Assessment. Washington, DC: The National Academies Press. https://www.nap.edu/catalog/12209/science-and-decisions-advancing-risk-assessment.
   Google Scholar
• Ortega, M. T., J. E. Riviere, K. Choi, and N. A. Monteiro-Riviere. 2017. “Biocorona Formation on Gold Nanoparticles Modulates Human Proximal Tubule Kidney Cell Uptake, Cytotoxicity and Gene Expression.” Toxicology In Vitro 42: 150–160.
   PubMed Web of Science ®Google Scholar
• Parveen, R., T. N. Shamsi, and S. Fatima. 2017. “Nanoparticles-Protein Interaction: Role in Protein Aggregation and Clinical Implications.” International Journal of Biological Macromolecules 94 (Pt A): 386–395.
   PubMedGoogle Scholar
• Pernodet, N., X. Fang, Y. Sun, A. Bakhtina, A. Ramakrishnan, J. Sokolov, A. Ulman, et al. 2006. “Adverse Effects of Citrate/Gold Nanoparticles on Human Dermal Fibroblasts.” Small 2 (6): 766–773.
   PubMed Web of Science ®Google Scholar
• Riviere, J. E. 2013. “Of Mice, Men and Nanoparticle Biocoronas: Are In Vitro to In Vivo Correlations and Interspecies Extrapolations Realistic? Nanomedicine (London) 8 (9): 1357–1359.
   PubMed Web of Science ®Google Scholar
• Sahneh, F. D., C. M. Scoglio, N. A. Monteiro-Riviere, and J. E. Riviere. 2015. “Predicting the Impact of Biocorona Formation Kinetics on Interspecies Extrapolations of Nanoparticle Biodistribution Modeling.” Nanomedicine (London) 10 (1): 25–33.
   PubMed Web of Science ®Google Scholar
• Schleh, C., M. Semmler-Behnke, J. Lipka, A. Wenk, S. Hirn, M. Schäffler, G. Schmid, et al. 2012. “Size and Surface Charge of Gold Nanoparticles Determine Absorption Across Intestinal Barriers and Accumulation in Secondary Target Organs after Oral Administration.” Nanotoxicology 6 (1): 36–46.
   PubMed Web of Science ®Google Scholar
• Sharma, V., and J. H. McNeill. 2009. “To Scale or Not to Scale: The Principles of Dose Extrapolation.” British Journal of Pharmacology 157 (6): 907–921.
   PubMed Web of Science ®Google Scholar
• Shi, Z., S. K. Chapes, D. Ben-Arieh, and C. H. Wu. 2016. “An Agent-Based Model of a Hepatic Inflammatory Response to Salmonella: A Computational Study under a Large Set of Experimental Data.” PLoS One 11 (8): e0161131.
   PubMed Web of Science ®Google Scholar
• Simpson, C. A., K. J. Salleng, D. E. Cliffel, and D. L. Feldheim. 2013. “In Vivo Toxicity, Biodistribution, and Clearance of Glutathione-Coated Gold Nanoparticles.” Nanomedicine 9 (2): 257–263.
   PubMed Web of Science ®Google Scholar
• Teeguarden, J. G., P. M. Hinderliter, G. Orr, B. D. Thrall, and J. G. Pounds. 2007. “Particokinetics In Vitro: Dosimetry Considerations for In Vitro Nanoparticle Toxicity Assessments.” Toxicological Sciences 95 (2): 300–312.
   PubMed Web of Science ®Google Scholar
• Westmeier, D., R. H. Stauber, and D. Docter. 2016. “The Concept of Bio-Corona in Modulating the Toxicity of Engineered Nanomaterials (ENM).” Toxicology and Applied Pharmacology 299: 53–57.
   PubMed Web of Science ®Google Scholar
• Wong, O. A., R. J. Hansen, T. W. Ni, C. L. Heinecke, W. S. Compel, D. L. Gustafson, C. J. Ackerson, et al. 2013. “Structure-Activity Relationships for biodistribution, Pharmacokinetics, and Excretion of Atomically Precise Nanoclusters in a Murine Model.” Nanoscale 5 (21): 10525–10533.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). 2009. Principles for Modelling Dose-Response for the Risk Assessment of Chemicals. International Programme on Chemical Safety. Geneva: WHO, 1–137. http://apps.who.int/iris/bitstream/10665/43940/1/9789241572392_eng.pdf.
   Google Scholar
• World Health Organization (WHO). 2010. Characterization and Application of Physiologically Based Pharmacokinetic Models in Risk Assessment. International Programme on Chemical Safety. Geneva: WHO, 1–91. http://www.who.int/ipcs/methods/harmonization/areas/pbpk_models.pdf?ua=1.
   Google Scholar
• Xu, C., G. A. Tung, and S. Sun. 2008. “Size and Concentration Effect of Gold Nanoparticles on X-Ray Attenuation as Measured on Computed Tomography.” Chemistry of Materials 20 (13): 4167–4169.
   PubMed Web of Science ®Google Scholar
• Zhang X.-D., D. Wu, X. Shen, P.-X. Liu, N. Yang, B. Zhao, H. Zhang, et al. 2011. “Size-Dependent In Vivo Toxicity of PEG-Coated Gold Nanoparticles.” International Journal of Nanomedicine 6: 2071–2081.
   PubMed Web of Science ®Google Scholar